In June 2021, the FDA issued a Class I recall for 15 million Philips Respironics CPAP, BiPAP, and mechanical ventilator devices—the highest severity designation used when a product creates reasonable probability of serious adverse health consequences or death. The recall was triggered by degradation of a polyester-based polyurethane (PE-PUR) sound abatement foam used in these devices, which could break down and release particles and volatile organic compounds into the air patients were breathing. This foam, present in devices manufactured between 2009 and 2021, affected millions of people who relied on these machines nightly to manage sleep apnea and other respiratory conditions. The human cost has been severe. As of September 2023, the FDA had received reports of 561 deaths associated with these recalled devices, with 187 additional deaths reported in 2023 alone among Philips CPAP and BiPAP users.
Beyond fatalities, over 116,000 medical device reports have been filed with the FDA documenting respiratory symptoms, cancer diagnoses, organ damage, and other serious health complications potentially linked to foam particle inhalation and chemical exposure. For patients like a 68-year-old CPAP user from Ohio who developed respiratory distress months after the recall announcement while continuing to use an unrepaired device, the delay between the recall and remediation availability created a dangerous window where people unknowingly continued exposing themselves to a hazardous product. In response to the mounting evidence of harm, Philips has faced significant litigation. A $1.1 billion settlement was announced in April 2024, with $1.075 billion earmarked specifically for personal injury claims. An earlier $479 million reimbursement settlement in September 2023 addressed consumers who had purchased, rented, or leased the recalled devices. However, as of April 2026, over 619 individual lawsuits remain pending in federal court, indicating that many victims believe the settlements do not adequately compensate them for their injuries and losses.
Table of Contents
- What Exactly Was Wrong With Philips Respironics Devices?
- Health Consequences and the Scope of Reported Injuries
- The Recall Process and Why Remediation Took So Long
- Settlement Money and How Claims Are Being Resolved
- Current Litigation Status and What’s Still Unresolved
- Identifying If You Have a Claim and Documentation Requirements
- The Broader Context—Regulatory Oversight and Future Safeguards
- Conclusion
What Exactly Was Wrong With Philips Respironics Devices?
The defect centered on a specific component: the sound abatement foam designed to make the machines quieter for patients trying to sleep. Philips used a polyester-based polyurethane (PE-PUR) material that degraded over time when exposed to heat, moisture, and normal use conditions. As the foam broke apart, it released fine particles that could be inhaled directly into a patient’s lungs during each breath. Additionally, the degrading foam released volatile organic compounds (VOCs)—gases with potential toxic effects—that concentrated inside the machine’s sealed breathing circuit.
The problem was not limited to a single model or a short manufacturing window. The recalled devices included popular models like the DreamStation and DreamStation2 CPAP and BiPAP machines, with the problematic foam present in approximately 15 million units manufactured between 2009 and 2021. A patient who purchased a Philips CPAP in 2015 and used it consistently might have had several years before foam degradation became visible or symptomatic, meaning harm could occur years after purchase without any obvious warning signs. Some patients reported seeing black or brown particles accumulating in the device tubing or mask, while others experienced respiratory symptoms without realizing their trusted medical device had become a source of contamination.
Health Consequences and the Scope of Reported Injuries
The health impacts reported by patients range from acute respiratory irritation to chronic conditions and cancer diagnoses. Respiratory complaints including coughing, wheezing, shortness of breath, and exacerbation of existing asthma have been commonly reported. More troubling are the cases involving suspected carcinogenic exposure: patients have developed lung cancer, mesothelioma, and other malignancies following years of CPAP use, raising questions about the long-term health effects of inhaling degraded polyurethane particles. A Pennsylvania man in his early 60s who had used a Philips device for over a decade developed lung cancer despite never smoking, with his medical team unable to rule out the CPAP foam exposure as a contributing factor.
The FDA’s database tells a stark story. Over 116,000 medical device reports have been received since April 2021, documenting respiratory symptoms, cancer claims, and organ damage. However, a critical limitation exists in interpreting these numbers: not all reported adverse events can be definitively causally linked to the foam degradation. Some patients experienced symptoms unrelated to their CPAP use; others had pre-existing conditions that may have contributed to their health decline. This causation question—proving that the foam particles or chemicals directly caused a specific patient’s disease—remains contested in litigation and represents one of the primary obstacles for claimants seeking compensation outside the settlement agreement.
The Recall Process and Why Remediation Took So Long
When Philips issued the recall in June 2021, they did not immediately have replacement devices available for all 15 million users. The remediation process involved either replacing the defective device with a repaired version or offering a replacement unit altogether. For many patients, this created a prolonged period—sometimes lasting months—during which they faced a difficult choice: continue using a device they now knew was potentially hazardous, or risk losing access to the medical equipment they depended on for health and safety. Some patients switched to alternative brands; others attempted repairs through third-party sources or simply continued using their recalled machines out of necessity or lack of awareness.
Philips’ remediation progress eventually reached approximately 99% of registered devices as of the latest publicly available updates. However, the device registration window itself closed on December 31, 2024, meaning that after this date, devices that had not been registered would no longer be eligible for remediation through the official Philips program. A patient who had stored an unused Philips CPAP and discovered it in late 2024, thinking they could still have it repaired, would have found themselves without recourse through the manufacturer’s remediation program. This timeline gap underscores a key limitation: the recall process could only reach patients who remained aware of the issue and took active steps to register and pursue remediation.
Settlement Money and How Claims Are Being Resolved
The legal resolution took multiple forms. The $479 million reimbursement settlement reached in September 2023 allowed consumers to seek reimbursement for the cost of recalled devices if they had purchased, rented, or leased them between 2008 and 2021. This was not compensation for injuries—it was money back for the defective equipment itself. A Florida resident who spent $1,200 on a CPAP machine in 2018 could potentially recover that amount through this settlement, provided they submitted proper documentation and met the eligibility criteria.
The larger $1.1 billion settlement announced in April 2024, which officially entered as a Master Settlement Agreement on May 9, 2024, was designed for personal injury claims. The $1.075 billion allocated for individual injury claims represents the mechanism through which seriously harmed patients could seek compensation beyond device refunds. However, the average payout per claim depends on the number of valid claims submitted and approved, and medical causation standards—proving the device caused the harm—create a filtering effect where not all claimants receive equal compensation. A patient with documented lung cancer who can establish that Philips foam particles were present in their lungs faces better odds than one with respiratory symptoms but no definitive medical proof of causation, illustrating the inherent inequality in settlement-based compensation systems.
Current Litigation Status and What’s Still Unresolved
As of April 2026, despite the two major settlements, 619 to 621 individual lawsuits remain pending in federal court in Western Pennsylvania. These cases represent plaintiffs who rejected the settlement offer, pursued individual claims, or filed lawsuits after settlement deadlines. A notable development occurred in January 2026 when a federal judge remanded a Kentucky cancer case back to state court, a decision that potentially signals growing uncertainty about whether all Philips cases will remain unified in federal multidistrict litigation (MDL). If more cases are remanded to state courts, litigation could become more fragmented, with different states and judges applying different standards for medical causation and damages.
One significant limitation in evaluating the settlements is the question of adequacy. Critics argue that $1.075 billion divided among potentially hundreds of thousands of eligible claimants results in insufficient compensation for severe injuries like cancer or respiratory failure. Philips’ position has been that the settlements represent fair resolution based on the evidence available and the company’s liability exposure. This disagreement continues to fuel the pending litigation, where some patients believe their specific injuries warrant individual judgment rather than participation in a collective settlement formula. The company also maintains that the foam degradation issue has been fully addressed in newer device models and through remediation of existing ones.
Identifying If You Have a Claim and Documentation Requirements
Determining eligibility for settlement compensation requires establishing several factual elements: ownership of a recalled Philips Respironics device manufactured during the affected years, documented health effects potentially connected to the device, and timely submission of a claim form. The settlement administrator’s website contains lists of recalled models and dates. A patient who used a recalled DreamStation CPAP from 2015 to 2021 and then developed respiratory symptoms or was diagnosed with a lung condition would need medical records documenting the diagnosis, any indication in those records of a possible environmental or inhalation exposure, and proof of device ownership or rental.
The critical challenge is demonstrating medical causation. You will need a treating physician’s opinion or medical records that support a potential link between device use and your health condition. Having a diagnosis alone is insufficient; the claim must establish temporal relationship (was the condition diagnosed after using the device?), symptom progression consistent with foam exposure, and ideally some medical evidence that foam particles or volatile compounds could have caused the specific condition. A claimant with only generic respiratory symptoms reported to a clinic visit may struggle, while one with specific medical documentation of inhalation injury following known device use would have a stronger case.
The Broader Context—Regulatory Oversight and Future Safeguards
The Philips Respironics recall highlighted gaps in how the FDA oversees ongoing device safety. Philips had received some adverse event reports prior to the June 2021 recall, but the company did not initiate the recall proactively; rather, independent investigations and media scrutiny created pressure for formal action. This raises questions about the balance between manufacturer responsibility and regulatory proactiveness. While the FDA approved these devices initially based on safety data available at the time of approval, the question of long-term foam stability in actual use conditions—exposed to repeated cycles of heating, humidification, and moisture—appears to have been inadequately evaluated before widespread deployment across millions of patients.
Moving forward, the recall has influenced medical device manufacturers and regulators to examine material selection more closely, particularly for components that directly contact or influence the air patients breathe. Alternative sound-dampening foams with greater chemical stability and resistance to degradation have been adopted by Philips and other manufacturers. However, these lessons came at a significant human cost—hundreds of deaths and serious illnesses that might have been prevented with stricter initial material qualification standards. For patients considering purchasing sleep apnea or respiratory devices, the Philips experience serves as a reminder that newer models from any manufacturer should be researched for post-market safety data and not automatically assumed to be safer than predecessors simply due to their release date.
Conclusion
The Philips Respironics recall represents one of the largest medical device safety failures in recent history, affecting 15 million users and resulting in 561 reported deaths and over 116,000 adverse event reports. The company’s $1.1 billion settlement addresses personal injuries and a separate $479 million settlement reimburses device costs, but as of April 2026, hundreds of individual lawsuits remain unresolved, indicating that many injured parties believe the settlements inadequately compensate their losses. The underlying cause—degraded polyester-based polyurethane foam releasing particles and volatile compounds—affected devices manufactured over a 12-year span, creating a prolonged window of exposure for patients who relied on these machines for daily respiratory support. If you own a recalled Philips Respironics device and have experienced health effects, step one is determining your device’s model and manufacturing date against the FDA’s recall list.
Step two is gathering medical documentation that establishes a temporal and clinical connection between your device use and your diagnosis. Step three is evaluating whether to pursue a settlement claim or join the remaining litigation. Each path carries different timelines, burden of proof, and potential compensation amounts. An attorney specializing in medical device litigation can review your specific circumstances and advise whether individual litigation, settlement participation, or a combination of both offers the best path forward. The window for settlement claims has already closed for many claims, but pending litigation continues, and the January 2026 Kentucky remand suggests that the legal landscape may continue to evolve as more cases are potentially decentralized to state courts.